Pulmonale Hypertension

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Assoz. Prof. Priv.-Doz. Dr. Nika Skoro-Sajer, MBA

Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Medizinische Universität Wien


  1. Shinya Y et al., A novel causative gene variant, TNFRSF13B p.Gly76Ser, in patients with pulmonary arterial hypertension. ESC 2020
  2. Mclaughlin V et al., Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs). ESC 2020
  3. Boretto P et al., Prognostic implication of sodium nitroprusside vasodilator test in pulmonary hypertension and left heart disease: insights from PUSHON registry. ESC 2020
  4. Sera F et al., Clinical characteristics and prognostic impact of pulmonary hypertension in heart failure with preserved ejection fraction: the PURSUIT HFpEF study. ESC 2020
  5. Galie N et al., Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: Insights from the randomised controlled TRITON study. ESC 2020
  6. Rosenkranz S et al., Effect of macitentan on left ventricular (LV) function in pulmonary arterial hypertension (PAH): results from REPAIR. ESC 2020
  7. Kimura M et al., De-escalation/discontinuation of oxygen-therapy and medication is feasible and safe in chronic thromboembolic pulmonary hypertension patients treated with balloon pulmonary angioplasty. ESC 2020

UIM 08|2020 Themenheft ESC

Herausgeber: o. Univ.-Prof. Dr. Günter J. Krejs
Publikationsdatum: 2020-10-27